<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.peertechzpublications.org/assets/xsl/oaitohtml.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
										<responseDate>2026-04-29T12:54:53Z</responseDate>
										<request verb="GetRecord" metadataPrefix="oai_dc" identifier="oai:www.peertechzpublications.org:10.17352/aaa.000005">https://www.peertechzpublications.org/oai-pmh</request><GetRecord><record>
								<header>
									<identifier>oai:www.peertechzpublications.org:10.17352/aaa.000005</identifier>
									<datestamp>2019-07-22</datestamp>
									<setSpec>PTZ.AAA:VOL3</setSpec>
								</header>
								<metadata>
									<oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
										<dc:title>
										Direct action antivirals are effective in the total eradication of HCV in renal transplants
										</dc:title><dc:creator>Teresa Olea</dc:creator><dc:creator> Inmaculada Castillo</dc:creator><dc:creator> Carlos Jiménez</dc:creator><dc:creator> Javier Bartolomé</dc:creator><dc:creator> María José Santana</dc:creator><dc:creator> JA Quiroga</dc:creator><dc:creator> Vicente Carreño</dc:creator><dc:creator>Rafael Selgas</dc:creator><dc:description>&lt;p&gt;&lt;strong&gt;Introduction&lt;/strong&gt;: The main objective of our study was to analyze the effectiveness of antiviral treatment (conventional or with direct-acting antivirals (DAA)) for total eradication of Hepatitis C Virus (HCV) in kidney transplant (KT) recipients. DAA are known drugs that are approved by FDA for clinical and preclinical&lt;/p&gt;&lt;p&gt;investigations. The effi cacy was analyzed by testing for the presence of HCV- ribonucleic acid (RNA) in the pellets obtained after ultracentrifugation of follow-up plasma samples and in peripheral blood mononuclear cells (PBMC) from patients with HCV infection who had achieved a sustained virological response (SVR). The safety, and the renal and hepatic repercussions of the antiviral treatment were also evaluated.&lt;/p&gt;</dc:description>
										<dc:publisher>Annals of Antivirals and Antiretrovirals - Peertechz Publications</dc:publisher>
										<dc:date>2019-07-22</dc:date>
										<dc:type>Research Article</dc:type>
										<dc:identifier>https://doi.org/10.17352/aaa.000005</dc:identifier>
										<dc:language>en</dc:language>
										<dc:rights>Copyright © Teresa Olea et al.</dc:rights>
									</oai_dc:dc>
								</metadata>
							</record></GetRecord>
						</OAI-PMH>
